Rigel Q4 2024 Earnings Report
Key Takeaways
Rigel reported record net product sales of $144.9 million, a 39% increase compared to 2023, and generated full-year net income of more than $17 million.
Total revenues were $57.6 million, including TAVALISSE net product sales were $31.0 million, REZLIDHIA net product sales were $7.4 million, and GAVRETO net product sales were $8.1 million.
TAVALISSE net product sales grew 21% compared to the same period of 2023.
REZLIDHIA net product sales grew 92% compared to the same period of 2023.
Rigel reported net income of $14.3 million, or $0.81 basic and $0.80 diluted per share.
Rigel
Rigel
Forward Guidance
Rigel anticipates 2025 total revenue of approximately $200 to $210 million, and anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.